Myriad Genetics (NASDAQ:MYGN) Updates Q4 2024 Earnings Guidance

Myriad Genetics (NASDAQ:MYGN) updated its fourth quarter 2024 earnings guidance on Wednesday. The company provided EPS guidance of 0.030-0.040 for the period, compared to the consensus EPS estimate of 0.030. The company issued revenue guidance of $209.0 million-$211.0 million, compared to the consensus revenue estimate of $212.8 million. Myriad Genetics also updated its FY 2025 guidance to 0.070-0.110 EPS.

Myriad Genetics Trading Down 4.8 %

Myriad Genetics stock opened at $12.52 on Friday. Myriad Genetics has a 12-month low of $12.17 and a 12-month high of $29.30. The firm has a 50-day moving average price of $14.78 and a 200-day moving average price of $21.97. The company has a debt-to-equity ratio of 0.05, a quick ratio of 1.73 and a current ratio of 1.90.

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on the stock. Stephens restated an “equal weight” rating and issued a $20.00 price target on shares of Myriad Genetics in a report on Thursday. StockNews.com raised shares of Myriad Genetics from a “hold” rating to a “buy” rating in a research report on Thursday, January 9th. Leerink Partners downgraded Myriad Genetics from an “outperform” rating to a “market perform” rating and reduced their price target for the stock from $30.00 to $21.00 in a research report on Monday, December 9th. Leerink Partnrs cut Myriad Genetics from a “strong-buy” rating to a “hold” rating in a research report on Monday, December 9th. Finally, Bank of America reduced their target price on Myriad Genetics from $15.00 to $13.00 and set an “underperform” rating on the stock in a research report on Friday, December 13th. Three equities research analysts have rated the stock with a sell rating, seven have issued a hold rating and four have assigned a buy rating to the company. According to MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $23.92.

About Myriad Genetics

Myriad Genetics, Inc, a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and pharmacogenomics. It also provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer.